Mirum Pharmaceuticals, Inc.
MIRM
$102.19
-$9.21-8.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 569.61M | 521.31M | 471.79M | 429.16M | 379.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 569.61M | 521.31M | 471.79M | 429.16M | 379.25M |
| Cost of Revenue | 106.03M | 100.24M | 94.76M | 90.03M | 86.83M |
| Gross Profit | 463.58M | 421.07M | 377.04M | 339.14M | 292.42M |
| SG&A Expenses | 295.65M | 257.03M | 239.73M | 228.37M | 214.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 639.73M | 538.45M | 508.59M | 481.24M | 450.57M |
| Operating Income | -70.12M | -17.14M | -36.79M | -52.08M | -71.32M |
| Income Before Tax | -797.46M | -21.43M | -40.83M | -57.36M | -75.91M |
| Income Tax Expenses | 1.38M | 1.94M | 593.00K | 1.20M | 1.44M |
| Earnings from Continuing Operations | -798.84 | -23.36 | -41.42 | -58.56 | -77.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -798.84M | -23.36M | -41.42M | -58.56M | -77.34M |
| EBIT | -70.12M | -17.14M | -36.79M | -52.08M | -71.32M |
| EBITDA | -45.05M | 7.11M | -12.57M | -27.86M | -47.30M |
| EPS Basic | -13.60 | -0.47 | -0.86 | -1.22 | -1.62 |
| Normalized Basic EPS | -0.78 | -0.21 | -0.47 | -0.68 | -0.93 |
| EPS Diluted | -13.62 | -0.49 | -0.87 | -1.22 | -1.62 |
| Normalized Diluted EPS | -0.79 | -0.21 | -0.47 | -0.68 | -0.93 |
| Average Basic Shares Outstanding | 209.42M | 199.45M | 196.78M | 193.92M | 191.43M |
| Average Diluted Shares Outstanding | 215.77M | 205.81M | 203.13M | 193.92M | 191.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |